114672-06-9 Usage
Uses
Used in Organic Synthesis:
ETHYL 1-(4-HYDROXYBENZYL)CYCLOBUTANE-1-CARBOXYLATE is used as a key intermediate in organic synthesis for the creation of various chemical compounds. Its unique structure allows for versatile reactions and the formation of a wide range of products.
Used in Pharmaceutical Research:
In the pharmaceutical industry, ETHYL 1-(4-HYDROXYBENZYL)CYCLOBUTANE-1-CARBOXYLATE is employed as a precursor in the development of new drugs. Its potential pharmacological properties make it a valuable asset in the search for novel therapeutic agents.
Used in Drug Development:
ETHYL 1-(4-HYDROXYBENZYL)CYCLOBUTANE-1-CARBOXYLATE is utilized as a building block in the synthesis of pharmaceuticals, contributing to the discovery and creation of innovative medications. Its role in drug development is crucial for advancing healthcare and improving treatment options.
The specific applications and properties of ETHYL 1-(4-HYDROXYBENZYL)CYCLOBUTANE-1-CARBOXYLATE may differ based on ongoing research and the particular requirements of each application. Its versatility and potential make it a compound of interest in the fields of chemistry and medicine.
Check Digit Verification of cas no
The CAS Registry Mumber 114672-06-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,4,6,7 and 2 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 114672-06:
(8*1)+(7*1)+(6*4)+(5*6)+(4*7)+(3*2)+(2*0)+(1*6)=109
109 % 10 = 9
So 114672-06-9 is a valid CAS Registry Number.
114672-06-9Relevant academic research and scientific papers
Alpha substituted carboxylic acids
-
, (2008/06/13)
Alpha substituted carboxylic acids of formula (I):
ALPHA SUBSTITUTED CARBOXYLIC ACID AS PPAR MODULATORS
-
Page 98, (2010/02/09)
Alpha substituted carboxylic acids of formula (I): wherein R' and R2 are as defined in the specification and R3 is A) formula (II); B) formula (III); C) formula (IV); and D) formula (V); wherein Y, Art, Are, AP, R4, R5, R6, R7, R6, R9, R9a, R10, R", R12, R17, ring A, and p are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR, specifically PPAR α/y related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.
